Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WHO Prequalifies Celltrion’s Rituximab

Truxima Becomes Second Biosimilar To Be Prequalified By Organization

Executive Summary

Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.

You may also be interested in...



IGBA Builds On Partnership With WHO

In the first in a series of exclusive interviews, IGBA chair Hanan Sboul talks about the international off-patent industry association’s collaboration with the WHO and how it is expected to develop in future.

WHO Prequalifies First Ever Biosimilar

Samsung Bioepis’ Ontruzant trastuzumab biosimilar has become the first biosimilar to be prequalified by the World Health Organization.

Samsung Bioepis’ Trastuzumab Prequalified By WHO

Samsung Bioepis’ Ontruzant trastuzumab biosimilar has become the first biosimilar to be prequalified by the World Health Organization.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel